<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04277221</url>
  </required_header>
  <id_info>
    <org_study_id>ADCTA-SSI-G1</org_study_id>
    <nct_id>NCT04277221</nct_id>
  </id_info>
  <brief_title>ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)</brief_title>
  <official_title>Autologous Dendritic Cell / Tumor Antigen (ADCTA-SSI-G1) for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM): A Multi-center, Open-label, Randomized Phase III Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Safe Save Medical Cell Sciences &amp; Technology Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Safe Save Medical Cell Sciences &amp; Technology Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To confirm the result of previous Phase I/II and phase II clinical trials, this trial is to
      test the efficacy and safety of ADCTA immunotherapy plus the standard therapy in comparison
      with standard therapy alone in patients with recurrent GBM.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>The duration will be calculated from the date of randomization until the date of death from any cause, assessed up to 60 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>The duration will be calculated from the date of randomization until the date of first documented progression according to the modified RANO or date of death from any cause, whichever came first,assessed up to 60 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival at 6 months (PFS6)</measure>
    <time_frame>The duration will be calculated from the date of randomization to the date of the sixth month.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 and 2-year Survival Rate</measure>
    <time_frame>The duration will be calculated from the date of randomization to the date of the first year and the second year.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Standard therapy with ADCTA vaccine (study group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- ADCTA vaccine as study treatment
Dose(s): Ten doses, including 2~4×10^7 cells for the 1st dose (double doses), and 1~2×10^7cells for the 2nd to 10th doses.
Administrative route: The ADCTA vaccine will be injected in axillar or inguinal regions close to lymphnodes subcutaneously at clinic.
Frequency: The primary immunization inoculation is followed by 3 vaccines bi-weekly and then 6 vaccines monthly inoculation, for a total of 10 doses.
- Bevacizumab as standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy (control group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No study treatment
Bevacizumab as standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Dendritic Cell/Tumor Antigen, ADCTA</intervention_name>
    <description>ADCTA is an individualized cell immunotherapy co-culturing autologous dendritic cells derived from peripheral blood mononuclear cells (PBMNCs) with autologous tumor cell as antigen in order to evoke specific immune response.</description>
    <arm_group_label>Standard therapy (control group)</arm_group_label>
    <arm_group_label>Standard therapy with ADCTA vaccine (study group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Specimen collection screening

               -  Karnofsky performance status (KPS) ≥ 60 at assessment prior to surgery

               -  ≥ 18 and ≤ 70 years of age

               -  Subject has been diagnosed with GBM and has undergone resection surgery followed
                  by standard brain RT + concurrent temozolomide and adjuvant temozolomide, and
                  progression occurred. The foregoing progression is defined as when patients with
                  primary GBM experience an image or clinical deterioration after receiving
                  standard of care.

               -  Contrast-enhanced MRI suspects recurrent GBM

               -  Supratentorial tumor

               -  Must voluntarily sign and date informed consent form for specimen acquisition and
                  future use, for study screening, approved by an Independent Ethics Committee
                  (IEC)/ Institutional Review Board (IRB), prior to the initiation of any
                  study-specific procedures

          2. Study screening

               -  Karnofsky performance status (KPS) ≥ 60 at randomization

               -  Submission of fresh tumor

               -  Post-operation contrast-enhanced MRI scan must be done after surgical resection,
                  with the intent for cyto-reduction ≥ 80% of the contrast-enhancing tumor mass

               -  Histologically confirmed WHO grade IV glioma by pathology tissue screening

               -  Subjects receiving bevacizumab as standard of care for given indication

               -  Subject has adequate bone marrow, renal, and hepatic function prior to
                  randomization as follow:

                    1. White blood cell (WBC) count ≥ 2,000/mm^3;

                    2. Absolute neutrophil count (ANC) ≥ 1,000/mm^3;

                    3. Platelets ≥ 100,000/mm^3;

                    4. Hemoglobin (Hgb) ≥ 8.0 g/dL (Note: The use of transfusion or other
                       intervention to achieve Hgb ≥ 8.0 g/dL is acceptable.);

                    5. Blood Urea Nitrogen (BUN) &lt; 30 mg/dL;

                    6. Creatinine &lt; 2 mg/dL;

                    7. Renal function: calculated creatinine clearance ≥ 30 mL/min;

                    8. Hepatic function: Total bilirubin ≤ 3 times upper limit of normal (ULN),
                       Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2
                       times ULN;

                    9. Prothrombin Time (PT) and activated partial thromboplastin time (PTT) ≤ 1.6
                       times ULN unless therapeutically warranted.

               -  Subjects with recurrent GBM (Grade IV) are eligible for this protocol. An
                  independent neuropathologist will review this diagnosis during the enrollment
                  process

               -  Must voluntarily sign and date informed consent form, for study participation,
                  approved by an Independent Ethics Committee (IEC)/ Institutional Review Board
                  (IRB), prior to the initiation of any study-specific procedures

        Exclusion Criteria:

          1. Specimen collection screening

               -  Multifocal GBM

               -  Prior invasive malignancy (except for non-melanomatous skin cancer; carcinoma in
                  situ of breast, oral cavity or cervix) unless disease free for ≥ 2 years

               -  Subject has used bevacizumab or immune checkpoint blockade to treat GBM

               -  Lactating or pregnant female

               -  Positive viral serology for HIV or syphilis at time of screening

          2. Study screening

               -  Subjects having a biopsy only at surgery or tumor cell insufficiency at
                  preparation

               -  Inability to undergo contrast-enhanced MRI scans

               -  Subjects receiving investigational study drug for any indication or
                  immunological-based treatment for any reason (Filgrastim may be used for
                  prevention of severe neutropenia)

               -  Inability to stop or decrease the use of corticosteroid doses to 4 mg/day prior
                  to randomization

               -  Tumor progression documented according to modified RANO criteria prior to
                  randomization (approximately 5 weeks after surgery)

               -  Severe, active comorbidity, defined as follow:

                    1. Subject with clinically defined Acquired Immune-Deficiency Syndrome
                       (AIDS)-defining illness;

                    2. Subjects with acute hepatitis C or B infection;

                    3. Severe hepatic impairment (Child-Pugh category C or higher);

                    4. Electrocardiogram (ECG) with evidence of acute cardiac ischemia prior to
                       randomization;

                    5. Transmural myocardial infarction or ischemia prior to enrollment;

                    6. Any other major medical illnesses or psychiatric impairments that in the
                       Investigator's opinion will prevent administration or completion of protocol
                       therapy

               -  Subject used Gliadel wafer implant in surgery during screening process
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peng-Wei Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wen-Kuang Yang, PhD</last_name>
    <phone>+886-3-5506696</phone>
    <email>wkyang@safesavecell.com.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weber Liu, MS</last_name>
    <phone>+886-3-5506696</phone>
    <email>wbliu@safesavecell.com.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Chiayi branch</name>
      <address>
        <city>Chiayi City</city>
        <zip>613</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen-Tsung Yang, MD/PhD</last_name>
      <phone>+886-5-3621000</phone>
    </contact>
    <investigator>
      <last_name>Jen-Tsung Yang, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Kaohsiung branch</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jih-Tsun Ho, MD/PhD</last_name>
      <phone>+886-7-7317123</phone>
    </contact>
    <investigator>
      <last_name>Jih-Tsun Ho, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Keelung branch</name>
      <address>
        <city>Keelung</city>
        <zip>204</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pin-Yuan Chen, MD/PhD</last_name>
      <phone>+886-2-24313131</phone>
    </contact>
    <investigator>
      <last_name>Pin-Yuan Chen, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiung-Chyi Shen, MD/PhD</last_name>
      <phone>+886-5-23592525</phone>
    </contact>
    <investigator>
      <last_name>Chiung-Chyi Shen, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wen-Yu Cheng, MD/PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan City</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E-Jian Lee, MD/PhD</last_name>
      <phone>+886-6-2353535</phone>
    </contact>
    <investigator>
      <last_name>E-Jian Lee, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tsai-Yun Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chia-Jui Yen, MD/PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center</name>
      <address>
        <city>Tainan City</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chin-Hong Chang, MD</last_name>
      <phone>+886-6-2812811</phone>
    </contact>
    <investigator>
      <last_name>Chin-Hong Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yin-Hsun Feng, MD/PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Linkou branch</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng-Wei Hsu, MD</last_name>
      <phone>+886-3-3281200</phone>
    </contact>
    <investigator>
      <last_name>Peng-Wei Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kuo-Chen Wei, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ying-Cheng Huang, MD/PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pin-Yuan Chen, MD/PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chi-Cheng Chuang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong-Chieh Tsai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheng-Chi Lee, MD/PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ko-Ting Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chi-Ting Liau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheng-Hong Toh, MD/PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, Kubota T, Yang WK. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci. 2011 Aug;18(8):1048-54. doi: 10.1016/j.jocn.2010.11.034. Epub 2011 Jun 28.</citation>
    <PMID>21715171</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>March 14, 2020</last_update_submitted>
  <last_update_submitted_qc>March 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent Glioblastoma Multiforme</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Dendritic Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

